Psychiatric manifestations of niemann - Pick disease

European Psychiatric Review

Volumn 4, Issue 1, 2011, Pages 25-31

  Webber, Daniel ^a   Klünemann, Hans H ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Glycosphingolipids; Lipid storage disorder; Neurological; Neuropsychiatric disorder; Niemann Pick disease type C

Indexed keywords

MIGLUSTAT;

ARTICLE; CLINICAL FEATURE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MENTAL DISEASE; MUTATOR GENE; NEUROPSYCHOLOGICAL TEST; NIEMANN PICK DISEASE; NONHUMAN; NPC1 GENE; NPC2 GENE; SYMPTOMATOLOGY;

EID: 84856255792     PISSN: 17581354     EISSN: 17581362     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Crocker AC, The cerebral defect in Tay-Sachs disease and Niemann-Pick disease, J Neurochem, 1961;7:69-80
2. Crocker AC, Mays VB, Sphingomyelin synthesis in Niemann-Pick disease, Am J Clin Nutr, 1961;9:63-7
3. Trendelenburg G, Vanier MT, Maza S, et al., Niemann-Pick type C disease in a 68-year-old patient, J Neurol Neurosurg Psychiatry, 2006;77:997-8.
4. Imrie J, Dasgupta S, Besley GT, et al., The natural history of Niemann-Pick disease type C in the UK, J Inherit Metab Dis, 2007;30:51-9.
5. Meikle PJ, Hopwood JJ, Clague AE, et al., Prevalence of lysosomal storage disorders, JAMA, 1999;281:249-54.
6. Pinto R, Caseiro C, Lemos M, et al., Prevalence of lysosomal storage diseases in Portugal, Eur J Hum Genet, 2004;12:87-92.
7. Vanier MT, Niemann-Pick disease type C, Orphanet J Rare Dis, 2010;5:16
8. Vanier MT, Millat G, Niemann-Pick disease type C, Clin Genet, 2003;64:269-81
9. Patterson MC, Vecchio D, Prady H, et al., Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study, Lancet Neurol, 2007;6:765-72.
10. Carstea ED, Morris JA, Coleman KG, et al., Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis, Science, 1997;277:228-31.
11. Higgins ME, Davies JP, Chen FW, et al., Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network, Mol Genet Metab, 1999;68:1-13.
12. Millat G, Marcais C, Tomasetto C, et al., Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop, Am J Hum Genet, 2001;68:1373-85.
13. Ko DC, Binkley J, Sidow A, et al., The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels, Proc Natl Acad Sci USA, 2003;100:2518-25.
14. Naureckiene S, Sleat DE, Lackland H, et al., Identification of HE1 as the second gene of Niemann-Pick C disease, Science, 2000;290:2298-301.
15. Carstea ED, Polymeropoulos MH, Parker CC, et al., Linkage of Niemann-Pick disease type C to human chromosome 18, Proc Natl Acad Sci USA, 1993;90:2002-4.
16. Kaminski WE, Klunemann HH, Ibach B, et al., Identification of novel mutations in the NPC1 gene in German patients with Niemann-Pick C disease, J Inherit Metab Dis, 2002;25:385-9.
17. Millat G, Marcais C, Rafi MA, et al., Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype, Am J Hum Genet, 1999;65:1321-9.
18. Klunemann HH, Elleder M, Kaminski WE, et al., Frontal lobe atrophy due to a mutation in the cholesterol binding protein HE1/NPC2, Ann Neurol, 2002;52:743-9.
19. Vanier MT, Duthel S, Rodriguez-Lafrasse C, et al., Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis, Am J Hum Genet, 1996;58:118-25.
20. Yamamoto T, Nanba E, Ninomiya H, et al., NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C, Hum Genet, 1999;105:10-6.
21. Pacheco CD, Lieberman AP, The pathogenesis of Niemann-Pick type C disease: a role for autophagy?, Expert Rev Mol Med, 2008;10:e26
22. Walkley SU, Suzuki K, Consequences of NPC1 and NPC2 loss of function in mammalian neurons, Biochim Biophys Acta, 2004;1685:48-62
23. Patterson MC, Vanier MT, Suzuki K, et al. (eds), Niemann-Pick disease type C: a lipid trafficking disorder. In: The Metabolic and Molecular Bases of Inherited Disease, New York: McGraw Hill, 16(145):3611-33.
24. Sevin M, Lesca G, Baumann N, et al., The adult form of Niemann-Pick disease type C, Brain, 2007;130:120-33.
25. Josephs KA, Van Gerpen MW, Van Gerpen JA, Adult onset Niemann-Pick disease type C presenting with psychosis, J Neurol Neurosurg Psychiatry, 2003;74:528-9
26. Walterfang M, Fietz M, Fahey M, et al., The neuropsychiatry of Niemann-Pick type C disease in adulthood, J Neuropsychiatry Clin Neurosci, 2006;18:158-70.
27. Walterfang M, Kornberg A, Adams S, et al., Post-ictal psychosis in adolescent Niemann-Pick disease type C, J Inherit Metab Dis, 2010;[Epub ahead of print].
28. Patterson MC, Platt F, Therapy of Niemann-Pick disease, type C, Biochim Biophys Acta, 2004;1685:77-82
29. Nixon RA, Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up, Am J Pathol, 2004;164:757-61
30. Goodrum JF, Pentchev PG, Cholesterol reutilization during myelination of regenerating PNS axons is impaired in Niemann-Pick disease type C mice, J Neurosci Res, 1997;49:389-92
31. German DC, Liang CL, Song T, et al., Neurodegeneration in the Niemann-Pick C mouse: glial involvement, Neuroscience, 2002;109:437-50.
32. Fan QW, Yu W, Gong JS, et al., Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons, J Neurochem, 2002;80:178-90.
33. Kalus P, Muller TJ, Zuschratter W, et al., The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients, Neuroreport, 2000;11:3621-5.
34. Rosoklija G, Toomayan G, Ellis SP, et al., Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings, Arch Gen Psychiatry, 2000;57:349-56.
35. Morell P, Jurevics H, Origin of cholesterol in myelin, Neurochem Res, 1996;21:463-70
36. Berger GE, Wood SJ, Pantelis C, et al., Implications of lipid biology for the pathogenesis of schizophrenia, Aust N Z J Psychiatry, 2002;36:355-66.
37. Tkachev D, Mimmack ML, Ryan MM, et al., Oligodendrocyte dysfunction in schizophrenia and bipolar disorder, Lancet, 2003;362:798-805.
38. Benes FM, Myelination of cortical-hippocampal relays during late adolescence, Schizophr Bull, 1989;15:585-93
39. Friston KJ, Frith CD, Schizophrenia: a disconnection syndrome?, Clin Neurosci, 1995;3:89-97
40. Pantelis C, Barnes TR, Nelson HE, et al., Frontal-striatal cognitive deficits in patients with chronic schizophrenia, Brain, 1997;120(10):1823-43.
41. Pacheco CD, Elrick MJ, Lieberman AP, Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis, Hum Mol Genet, 2009;18:956-65
42. Burns M, Gaynor K, Olm V, et al., Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo, J Neurosci, 2003;23:5645-9.
43. Kuo YM, Emmerling MR, Bisgaier CL, et al., Elevated lowdensity lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels, Biochem Biophys Res Commun, 1998;252:711-5.
44. Saito Y, Suzuki K, Nanba E, et al., Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity, Ann Neurol, 2002;52:351-5.
45. Shulman LM, David NJ, Weiner WJ, Psychosis as the initial manifestation of adult-onset Niemann-Pick disease type C, Neurology, 1995;45:1739-43
46. Vanier MT, Rodriguez-Lafrasse C, Rousson R, et al., Type C Niemann-Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL-derived cholesterol processing, Biochim Biophys Acta, 1991b;1096:328-37.
47. Vanier MT, Wenger DA, Comly ME, et al., Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients, Clin Genet, 1988;33:331-48.
48. Yan-Go FL, Yanagihara T, Pierre RV, et al., A progressive neurologic disorder with supranuclear vertical gaze paresis and distinctive bone marrow cells, Mayo Clin Proc, 1984;59:404-10.
49. Campo JV, Stowe R, Slomka G, et al., Psychosis as a presentation of physical disease in adolescence: a case of Niemann-Pick disease, type C, Dev Med Child Neurol, 1998;40:126-9.
50. Sandu S, Jackowski-Dohrmann S, Ladner A, et al., Niemann-Pick disease type C1 presenting with psychosis in an adolescent male, Eur Child Adolesc Psychiatry, 2009;18:583-5.
51. Imrie J, Vijayaraghaven S, Whitehouse C, et al., Niemann-Pick disease type C in adults, J Inherit Metab Dis, 2002;25:491-500.
52. Ahmad I, Lope-Piedrafita S, Bi X, et al., Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice, J Neurosci Res, 2005;82:811-21.
53. Bascunan-Castillo EC, Erickson RP, Howison CM, et al., Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C, J Appl Genet, 2004;45:461-7.
54. Hinton V, Vecchio D, Prady H, et al., The cognitive phenotype of type C disease: neuropsychological characteristics of patients at baseline in a clinical trial with oral miglustat, American Society of Human Genetics, Conference, Salt Lake City, Uhah: 2005.
55. Klarner B, Klunemann HH, Lurding R, et al., Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations, J Inherit Metab Dis, 2007;30:60-7.
56. Wraith JE, Baumgartner MR, Bembi B, et al., Recommendations on the diagnosis and management of Niemann-Pick disease type C, Mol Genet Metab, 2009;98:152-65.
57. Kandt RS, Emerson RG, Singer HS, et al., Cataplexy in variant forms of Niemann-Pick disease, Ann Neurol, 1982;12:284-8.
58. NPC-info.com, Actelion Pharmaceuticals Ltd, Available at: www.niemann-pick-c.com/(22 February 2011).
59. Kim SJ, Lee BH, Lee YS, et al., Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor, Biochem Biophys Res Commun, 2007;360:593-9.
60. Butters TD, Dwek RA, Platt FM, Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders, Chem Rev, 2000;100:4683-96
61. Platt FM, Neises GR, Dwek RA, et al., N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J Biol Chem, 1994a;269:8362-5.
62. Platt FM, Neises GR, Karlsson GB, et al., Nbutyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, J Biol Chem, 1994b;269:27108-14.
63. Patterson MC, Vecchio D, Jacklin E, et al., Long-term miglustat therapy in children with Niemann-Pick disease type C, J Child Neurol, 2010;25:300-5.
64. Pineda M, Wraith JE, Mengel E, et al., Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study, Mol Genet Metab, 2009;98:243-9.
65. Wraith JE, Vecchio D, Jacklin E, et al., Miglustat in adult and juvenile patients with Niemann-Pick disease type C: longterm data from a clinical trial, Mol Genet Metab, 2010;99:351-7.
66. Pineda M, Perez-Poyato MS, O'Callaghan M, et al., Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series, Mol Genet Metab, 2010;99:358-66.
67. Barranger JM, Novelli EA, Gene therapy for lysosomal storage disorders, Expert Opin Biol Ther, 2001;1:857-67
68. Cabrera-Salazar MA, Novelli E, Barranger JA, Gene therapy for the lysosomal storage disorders, Curr Opin Mol Ther, 2002;4:349-58
69. Galli R, Gritti A, Bonfanti L, et al., Neural stem cells: an overview, Circ Res, 2003;92:598-608.
70. Snyder EY, Taylor RM, Wolfe JH, Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain, Nature, 1995;374:367-70
71. Bonney DK, O'Meara A, Shabani A, et al., Successful allogeneic bone marrow transplant for Niemann-Pick disease type C2 is likely to be associated with a severe 'graft versus substrate' effect, J Inherit Metab Dis, 2010; [Epub ahead of print].
72. Smith D, Wallom KL, Williams IM, et al., Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1, Neurobiol Dis, 2009;36:242-51.
73. Reddy JV, Ganley IG, Pfeffer SR, Clues to neurodegeneration in Niemann-Pick type C disease from global gene expression profiling, PLoS One, 2006;1:e19
74. Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine. 2010; http://clinicaltrials.gov/ct2/show/NCT00975689 (date accessed: 18 March 2011).
75. Alvarez AR, Klein A, Castro J, et al., Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease, FASEB J, 2008;22:3617-27.
76. Griffin LD, Gong W, Verot L, et al., Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone, Nat Med, 2004;10:704-11.
77. Mellon SH, Gong W, Schonemann MD, Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease, Brain Res Rev, 2008;57:410-20
78. Liu B, Ramirez CM, Miller AM, et al., Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid, J Lipid Res, 2010;51:933-44.
79. Liu B, Turley SD, Burns DK, et al., Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse, Proc Natl Acad Sci USA, 2009;106:2377-82.
80. Sullivan D, Walterfang M, Velakoulis D, Bipolar disorder and Niemann-Pick disease type C, Am J Psychiatry, 2005;162:1021-2
81. Battisti C, Tarugi P, Dotti MT, et al., Adult onset Niemann-Pick type C disease: A clinical, neuroimaging and molecular genetic study, Mov Disord, 2003;18:1405-9.
82. Love S, Bridges LR, Case CP, Neurofibrillary tangles in Niemann-Pick disease type C, Brain, 1995;118(Pt1):119-29
83. Vanier MT, Rodriguez-Lafrasse C, Rousson R, et al., Type C Niemann-Pick disease: biochemical aspects and phenotypic heterogeneity, Dev Neurosci, 1991a;13:307-14.
84. Corrigan JD, Hinkeldey NS, Relationships between parts A and B of the Trail Making Test, J Clin Psychol, 1987;43:402-9
85. Ardila A, Ostrosky-Solis F, Bernal B, Cognitive testing toward the future: The example of Semantic Verbal Fluency (ANIMALS), Int J Psychol, 2006;41:324-32
86. Berch DB, Krikorian R, Huha EM, The Corsi block-tapping task: methodological and theoretical considerations, Brain Cogn, 1998;38(3):317-38
87. Folstein MF, Folstein SE, McHugh PR, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 1975;12:189-98.
88. Shulman KI, Clock-drawing: is it the ideal cognitive screening test?, Int J Geriatr Psychiatry, 2000;15:548-61